RegenxBio has patented a method for treating mucopolysaccharidosis II (MPS II) by delivering recombinant human iduronate-2-sulfatase to the central nervous system. The method involves measuring D2S6 levels in a biological sample, diagnosing MPS II, and calculating a ratio of D2S6 to total heparan sulfate disaccharides. GlobalData’s report on RegenxBio gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on RegenxBio, Adeno-associated virus vectors was a key innovation area identified from patents. RegenxBio's grant share as of May 2024 was 7%. Grant share is based on the ratio of number of grants to total number of patents.
Treating mps ii by delivering hids to cns
A recently granted patent (Publication Number: US11986515B2) outlines a method for treating mucopolysaccharidosis II (MPS II) in human subjects. The method involves measuring the level of D2S6 in a biological sample obtained from the subject, diagnosing MPS II based on the D2S6 level exceeding a reference value, and delivering an effective amount of human iduronate-2-sulfatase (hIDS) to the central nervous system (CNS) of the diagnosed subject. The ratio of D2S6 to total heparan sulfate disaccharides (HS) in the sample is also calculated as part of the method.
Furthermore, the patent details various delivery methods for the active hIDS, including the use of adeno-associated virus (AAV) vectors or enzyme replacement therapy. Monitoring the D2S6 levels post-treatment is crucial, with a decrease indicating successful treatment. The method also specifies different age groups for the human subjects, ranging from adults to children as young as 4 months old. Overall, the patent provides a comprehensive approach to treating MPS II by targeting the CNS with active hIDS and monitoring treatment efficacy through D2S6 levels in biological samples obtained from the subjects.
To know more about GlobalData’s detailed insights on RegenxBio, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
